Press Releases + News

Date	Title and Summary	View
Toggle SummaryJul 15, 2015	Galectin Therapeutics Inc. Appoints Adam E. Allgood, Pharm.D., R.Ph., as Executive Director of Clinical Development	View HTML Galectin Therapeutics Inc. Appoints Adam E. Allgood, Pharm.D., R.Ph., as Executive Director of Clinical Development 23.6 KB
Toggle SummaryJun 29, 2015	Galectin Therapeutics Initiates Enrollment for GR-MD-02 Phase 2 Clinical Trial in NASH with Cirrhosis First Five Patients Screened	View HTML Galectin Therapeutics Initiates Enrollment for GR-MD-02 Phase 2 Clinical Trial in NASH with Cirrhosis 30.9 KB
Toggle SummaryJun 03, 2015	Galectin Therapeutics Names Dr. Marc Rubin Lead Independent Director	View HTML Galectin Therapeutics Names Dr. Marc Rubin Lead Independent Director 27.4 KB
Toggle SummaryMay 28, 2015	Galectin Therapeutics to Present at LD Micro Invitational Conference	View HTML Galectin Therapeutics to Present at LD Micro Invitational Conference 19.2 KB
Toggle SummaryMay 15, 2015	Galectin Therapeutics to Webcast Corporate Update Following Annual Meeting of Stockholders	View HTML Galectin Therapeutics to Webcast Corporate Update Following Annual Meeting of Stockholders 20.6 KB
Toggle SummaryMay 14, 2015	Galectin Therapeutics Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam Phase 1 Pharmacokinetic Study Conducted in Accordance With FDA Requirements; Results Add to the GR-MD-02 Safety Profile and Allow for Expansion of Number of Patients Eligible to be Included in Phase 2 Clinical Trials	View HTML Galectin Therapeutics Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam 18.9 KB
Toggle SummaryMay 11, 2015	Galectin Therapeutics Reports First Quarter 2015 Financial Results, Provides Business Update Including Phase 2 NASH Program	View HTML Galectin Therapeutics Reports First Quarter 2015 Financial Results, Provides Business Update Including Phase 2 NASH Program 34.8 KB
Toggle SummaryMar 24, 2015	Galectin Therapeutics Presented Research With GR-MD-02 at the American Association for the Study of Liver Diseases Industry Colloquium	View HTML Galectin Therapeutics Presented Research With GR-MD-02 at the American Association for the Study of Liver Diseases Industry Colloquium 19 KB
Toggle SummaryMar 18, 2015	Galectin Therapeutics Reports 2014 Financial Results, Provides Business Update	View HTML Galectin Therapeutics Reports 2014 Financial Results, Provides Business Update 32 KB
Toggle SummaryMar 12, 2015	Galectin Therapeutics Engages PPD to Conduct GR-MD-02 Phase 2 Trial in NASH, Submits Special Protocol Assessment to FDA Study Enrollment to Begin in the Second Quarter	View HTML Galectin Therapeutics Engages PPD to Conduct GR-MD-02 Phase 2 Trial in NASH, Submits Special Protocol Assessment to FDA 28.1 KB